FDA Rejects Application for Psychedelic Drug
HKLaw
AUGUST 11, 2024
The U.S. Food and Drug Administration (FDA) rejected the new drug application (NDA) for a drug marketing approval submitted by Lykos Therapeutics Inc. for its psychedelic MDMA drug to treat post-traumatic stress disorder (PTSD).
Let's personalize your content